On June 17, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over a 12-month period starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7, 2024, and August 5, 2024. As of June 14, 2024, Novo Nordisk has repurchased 9,703,295 B shares at an average price of DKK 868.99 per share, totaling DKK 8,432,046,688. The transactions are in line with the Safe Harbour Rules of the European Union. Following these transactions, Novo Nordisk holds 11,068,859 B shares as treasury shares, which is 0.2% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.

On June 17, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over a 12-month period starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7, 2024, and August 5, 2024. As of June 14, 2024, Novo Nordisk has repurchased 9,703,295 B shares at an average price of DKK 868.99 per share, totaling DKK 8,432,046,688. The transactions are in line with the Safe Harbour Rules of the European Union. Following these transactions, Novo Nordisk holds 11,068,859 B shares as treasury shares, which is 0.2% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.